Your browser doesn't support javascript.
loading
Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria.
Chalupka, Alena; Richter, Lukas; Chakeri, Ali; El-Khatib, Ziad; Theiler-Schwetz, Verena; Trummer, Christian; Krause, Robert; Willeit, Peter; Benka, Bernhard; Ioannidis, John P A; Pilz, Stefan.
Afiliação
  • Chalupka A; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.
  • Richter L; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.
  • Chakeri A; Institute of Statistics, Graz University of Technology, Graz, Austria.
  • El-Khatib Z; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.
  • Theiler-Schwetz V; Center for Public Health, Medical University Vienna, Vienna, Austria.
  • Trummer C; Institute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.
  • Krause R; Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
  • Willeit P; Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
  • Benka B; Department of Internal Medicine, Division of Infectious Diseases, Medical University of Graz, Graz, Austria.
  • Ioannidis JPA; Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria.
  • Pilz S; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Eur J Clin Invest ; 54(3): e14136, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38032853

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article